Cargando…
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
BACKGROUND: Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown. METHODS: In the UK context, we performed a budget im...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503472/ https://www.ncbi.nlm.nih.gov/pubmed/23180971 http://dx.doi.org/10.2147/CEOR.S37205 |
_version_ | 1782250450198724608 |
---|---|
author | Thorlund, Kristian Druyts, Eric El Khoury, Antoine C Mills, Edward J |
author_facet | Thorlund, Kristian Druyts, Eric El Khoury, Antoine C Mills, Edward J |
author_sort | Thorlund, Kristian |
collection | PubMed |
description | BACKGROUND: Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown. METHODS: In the UK context, we performed a budget impact analysis to estimate the average per patient cost of adding boceprevir or telaprevir to PEGylated interferon plus ribavirin therapy. We considered both standard-duration therapy and response-guided therapy regimens of boceprevir and telaprevir for treatment-naïve and treatment-experienced patients. Our model utilized monthly discontinuation rates. We built a Bayesian Markov model to account for uncertainty associated with the clinical input and cost data. RESULTS: The total average cost of response-guided therapy with boceprevir is £22,850 and £25,060 for treatment-naïve and treatment-experienced patients, respectively. By comparison, the total average cost of response-guided therapy with telaprevir was £29,930 and £31,880 for treatment-naïve and treatment-experienced patients, respectively, whereas the total average cost of standard-duration boceprevir is £34,680 and £34,350 and for telaprevir was £32,530 and £31,680 for treatment-naïve and treatment experienced patients, respectively. CONCLUSION: Our results demonstrate that response-guided therapy with boceprevir is notably less costly than response-guided therapy with telaprevir. Our results also suggest that the standard treatment duration of boceprevir is slightly more costly than the standard treatment duration of telaprevir. |
format | Online Article Text |
id | pubmed-3503472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35034722012-11-23 Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection Thorlund, Kristian Druyts, Eric El Khoury, Antoine C Mills, Edward J Clinicoecon Outcomes Res Original Research BACKGROUND: Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown. METHODS: In the UK context, we performed a budget impact analysis to estimate the average per patient cost of adding boceprevir or telaprevir to PEGylated interferon plus ribavirin therapy. We considered both standard-duration therapy and response-guided therapy regimens of boceprevir and telaprevir for treatment-naïve and treatment-experienced patients. Our model utilized monthly discontinuation rates. We built a Bayesian Markov model to account for uncertainty associated with the clinical input and cost data. RESULTS: The total average cost of response-guided therapy with boceprevir is £22,850 and £25,060 for treatment-naïve and treatment-experienced patients, respectively. By comparison, the total average cost of response-guided therapy with telaprevir was £29,930 and £31,880 for treatment-naïve and treatment-experienced patients, respectively, whereas the total average cost of standard-duration boceprevir is £34,680 and £34,350 and for telaprevir was £32,530 and £31,680 for treatment-naïve and treatment experienced patients, respectively. CONCLUSION: Our results demonstrate that response-guided therapy with boceprevir is notably less costly than response-guided therapy with telaprevir. Our results also suggest that the standard treatment duration of boceprevir is slightly more costly than the standard treatment duration of telaprevir. Dove Medical Press 2012-11-16 /pmc/articles/PMC3503472/ /pubmed/23180971 http://dx.doi.org/10.2147/CEOR.S37205 Text en © 2012 Thorlund et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Thorlund, Kristian Druyts, Eric El Khoury, Antoine C Mills, Edward J Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection |
title | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection |
title_full | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection |
title_fullStr | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection |
title_full_unstemmed | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection |
title_short | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection |
title_sort | budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis c genotype 1 infection |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503472/ https://www.ncbi.nlm.nih.gov/pubmed/23180971 http://dx.doi.org/10.2147/CEOR.S37205 |
work_keys_str_mv | AT thorlundkristian budgetimpactanalysisofboceprevirandtelaprevirforthetreatmentofhepatitiscgenotype1infection AT druytseric budgetimpactanalysisofboceprevirandtelaprevirforthetreatmentofhepatitiscgenotype1infection AT elkhouryantoinec budgetimpactanalysisofboceprevirandtelaprevirforthetreatmentofhepatitiscgenotype1infection AT millsedwardj budgetimpactanalysisofboceprevirandtelaprevirforthetreatmentofhepatitiscgenotype1infection |